Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anti PD-1”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06425926
What this trial is testing

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

Who this might be right for
Melanoma Stage IVSolid Tumor
Georgiamune Inc 117
Early research (Phase 1)UnknownNCT04866485
What this trial is testing

Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Who this might be right for
Solid Tumor
Harbour BioMed (Guangzhou) Co. Ltd. 66
Testing effectiveness (Phase 2)Study completedNCT02843204
What this trial is testing

Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors

Who this might be right for
Malignant Solid Tumour
Fuda Cancer Hospital, Guangzhou 110
Testing effectiveness (Phase 2)WithdrawnNCT03014804
What this trial is testing

Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Who this might be right for
Giant Cell GlioblastomaGliosarcomaOligodendroglioma+2 more
Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)UnknownNCT04413838
What this trial is testing

Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection

Who this might be right for
Obesity, COVID-19 Infection
Hospices Civils de Lyon 120
Not applicableActive Not RecruitingNCT06865521
What this trial is testing

Akkermansia Probiotics Plus Anti-PD-1 Monoclonal Antibody in MSS/pMMR Advanced Colorectal Cancer

Who this might be right for
Colo-rectal CancerPD-1 InhibitorAkkermansia Muciniphila
West China Hospital 22
Testing effectiveness (Phase 2)UnknownNCT03898895
What this trial is testing

COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable Biliary Tract Cancer

Who this might be right for
Biliary Tract CancerRadiotherapyImmunotherapy
Sun Yat-sen University 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT02743819
What this trial is testing

Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma

Who this might be right for
Melanoma
University of Chicago 70
Early research (Phase 1)Ended earlyNCT03978611
What this trial is testing

Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Who this might be right for
Melanoma
Bristol-Myers Squibb 11
Testing effectiveness (Phase 2)WithdrawnNCT04001101
What this trial is testing

Anti-PD-1 +/- RT for MSI-H Solid Tumors

Who this might be right for
Microsatellite Instability HighMismatch Repair DeficiencyColorectal Cancer
University of Colorado, Denver
Testing effectiveness (Phase 2)Study completedNCT04886271
What this trial is testing

Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Hangzhou Hanx Biopharmaceuticals, Ltd. 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT07686796
What this trial is testing

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Who this might be right for
Local Advanced Rectal CancerPD-1 InhibitorPCSK9 Inhibitor+4 more
Guangdong Provincial People's Hospital 148
Not applicableEnded earlyNCT04473027
What this trial is testing

BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs

Who this might be right for
MelanomaCancer
University Hospital, Ghent 3
Large-scale testing (Phase 3)WithdrawnNCT04943627
What this trial is testing

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Who this might be right for
Advanced CancerMetastatic Cervical Cancer
Agenus Inc.
Large-scale testing (Phase 3)UnknownNCT05661240
What this trial is testing

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd 348
Testing effectiveness (Phase 2)Looking for participantsNCT07281924
What this trial is testing

Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis

Who this might be right for
Metastatic MelanomaLiver Metastases
University of Wisconsin, Madison 15
Testing effectiveness (Phase 2)Looking for participantsNCT06413680
What this trial is testing

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Who this might be right for
MelanomaClear-Cell Renal-Cell Carcinoma (ccRCC)Advanced Solid Tumors
Regeneron Pharmaceuticals 240
Early research (Phase 1)UnknownNCT04059874
What this trial is testing

Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate

Who this might be right for
Non-small Cell Lung Cancer
First Affiliated Hospital of Zhejiang University 20
Testing effectiveness (Phase 2)Looking for participantsNCT06638931
What this trial is testing

Agnostic Therapy in Rare Solid Tumors

Who this might be right for
Urachal CancerParathyroid CarcinomaFibrolamellar Carcinoma+38 more
Instituto do Cancer do Estado de São Paulo 28
Large-scale testing (Phase 3)Active Not RecruitingNCT05732805
What this trial is testing

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Who this might be right for
MelanomaMelanoma (Skin)Melanoma Stage III+4 more
Biocad 270
Next Page